- Home
- TPG vs IONS Comparison
TPG vs IONS Comparison
Compare TPG & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPG
- IONS
- Stock Information
- Founded
- TPG 1992
- IONS 1989
- Country
- TPG United States
- IONS United States
- Employees
- TPG N/A
- IONS N/A
- Industry
- TPG Investment Managers
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- TPG Finance
- IONS Health Care
- Exchange
- TPG Nasdaq
- IONS Nasdaq
- Market Cap
- TPG 6.6B
- IONS 5.4B
- IPO Year
- TPG 2022
- IONS 1991
- Fundamental
- Price
- TPG $48.13
- IONS $33.51
- Analyst Decision
- TPG Buy
- IONS Buy
- Analyst Count
- TPG 12
- IONS 18
- Target Price
- TPG $62.36
- IONS $57.41
- AVG Volume (30 Days)
- TPG 2.4M
- IONS 1.5M
- Earning Date
- TPG 05-07-2025
- IONS 04-30-2025
- Dividend Yield
- TPG 3.62%
- IONS N/A
- EPS Growth
- TPG N/A
- IONS N/A
- EPS
- TPG N/A
- IONS N/A
- Revenue
- TPG $3,710,887,000.00
- IONS $717,253,000.00
- Revenue This Year
- TPG N/A
- IONS $7.14
- Revenue Next Year
- TPG $24.30
- IONS $18.89
- P/E Ratio
- TPG $16,303.55
- IONS N/A
- Revenue Growth
- TPG 44.34
- IONS N/A
- 52 Week Low
- TPG $37.52
- IONS $23.95
- 52 Week High
- TPG $72.98
- IONS $52.34
- Technical
- Relative Strength Index (RSI)
- TPG 49.12
- IONS 56.80
- Support Level
- TPG $47.20
- IONS $32.00
- Resistance Level
- TPG $48.53
- IONS $33.65
- Average True Range (ATR)
- TPG 1.28
- IONS 1.08
- MACD
- TPG -0.30
- IONS -0.10
- Stochastic Oscillator
- TPG 24.54
- IONS 55.72
About TPG TPG Inc.
TPG Inc is an alternative asset firm. It invests across five multi-product platforms namely Capital, Growth, Impact, Real Estate, and Market Solutions. TPG aims to build dynamic products and options for its clients while also instituting discipline and operational excellence across the investment and performance of its portfolio.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.